<DOC>
	<DOCNO>NCT02975973</DOCNO>
	<brief_summary>Cognitive impairment schizophrenia debilitate aspect illness poorly treat current medication . This study investigate transcranial direct current stimulation ( tDCS ) - safe , noninvasive weak electrical current delivery stimulate brain function - novel therapeutic cognition schizophrenia . Integrating neurostimulation , electrophysiology neuroimaging , project aim study tDCS effect cognition verify therapeutic target engagement , evaluate tolerability tDCS session , optimize treatment parameter .</brief_summary>
	<brief_title>Prefrontal Cortical Engagement Through Non-Invasive Brain Stimulation Schizophrenia</brief_title>
	<detailed_description>Cognitive deficit strong predictor functional outcome schizophrenia , yet poorly remediate current treatment . Disturbances dorsolateral prefrontal cortex ( DLPFC ) function underlie core impairment cognitive control thus represent critical target novel therapeutic . Initial study indicate transcranial direct-current stimulation ( tDCS ) may effective reducing symptom due DLPFC dysfunction . While tDCS potentially represent exciting , novel therapeutic advance , number basic question address prior conduct larger-scale clinical trial , include : verifying therapeutic target engagement , optimize treatment parameter , evaluate meaningful clinical effect . Recent study employ tDCS enhance prefrontal cortical function schizophrenia apply stimulate electrode leave frontal scalp region , putatively target leave DLPFC . However , explicit confirmation target engagement lacking . Further , EEG study demonstrate close link frontal cortical gamma oscillation cognitive control process modulation critical physiologic process investigate . Accordingly , primary aim study employ multimodal image explicitly test assume DLPFC engagement ( fMRI ) modulation frontal gamma activity ( EEG ) tDCS . This study also investigate optimization tDCS application parameter . Analogous dose-finding investigation drug study , conduct parametric investigation optimal current strength . Also , extensive evidence tolerability single session tDCS , confirmation feasibility multisession optimize protocol schizophrenia lack explicitly evaluate . In summary , successful outcome study would provide tDCS sound mechanistic methodologic basis definitive test large-scale clinical trial highly innovative therapeutic intervention cognitive impairment schizophrenia .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1. age 1835 year ; 2. within first five year antipsychotic treatment ; 3. stable dos secondgeneration antipsychotic medication least one month ; 4 . Clinically stable define Clinical Global Impression−Severity scale ( CGI−S ) less equal 4 ( moderately ill ) ; 5 . Mild severe cognitive impairment MATRICS Consensus Cognitive Battery ( composite score &lt; 40 ) ; 6 . DSM5 criterion schizophrenia schizoaffective patient SCID 1 . DSM5 mental retardation ; 2. significant head injury ; 3 . History severe medical neurological illness 4. pregnancy postpartum ( &lt; 6 week delivery miscarriage ) ; 5. inability provide inform consent ; 6. significant color blindness affect task performance ; 7 . Positive urine drug screen ( exception marijuana ) presence substance use disorder within 3 month ; 8 . Currently benzodiazepines mood stabilizer affect GABA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>tDCS</keyword>
	<keyword>cognitive control</keyword>
	<keyword>EEG</keyword>
	<keyword>gamma oscillation</keyword>
</DOC>